ARKG vs XBI

Key Takeaways

• ARK Genomic Revolution ETF (ARKG) is an actively managed thematic fund focused on the genomics revolution, while SPDR S&P Biotech ETF (XBI) is a passively managed fund tracking a modified equal-weighted biotechnology index.
• ARKG maintains a concentrated portfolio of approximately 30–40 holdings with top positions often exceeding 8–9% each, whereas XBI holds roughly 150 stocks with no single position dominating beyond 1.5%.
• ARKG carries a higher expense ratio of 0.75% compared to XBI’s 0.35%, reflecting its active management approach versus XBI’s passive index-tracking structure.
• Both ETFs provide exposure to the biotechnology sector, but ARKG emphasizes smaller, innovative genomics companies across healthcare and related fields, while XBI offers broader diversification within pure-play U.S. biotechnology firms.
• XBI’s equal-weighted methodology reduces concentration risk relative to ARKG’s active selection, though both funds exhibit elevated volatility typical of the biotech sector.
• Structural differences in management style, cost, and diversification position the two ETFs as complementary rather than direct substitutes for investors seeking biotech or genomics exposure.

Introduction

ARK Genomic Revolution ETF (ARKG) and SPDR S&P Biotech ETF (XBI) both target the biotechnology and life-sciences space, yet they pursue distinct strategies within the sector. ARKG employs active management to capture innovation in genomics, while XBI provides passive, rules-based exposure to a broad biotechnology index. These ETFs do not compete head-to-head but instead offer investors alternative approaches to similar thematic goals: participation in advances in gene editing, diagnostics, and therapeutic development. The comparison highlights trade-offs in cost, diversification, and active versus passive implementation that matter for portfolio construction in the healthcare innovation landscape.

ARK Genomic Revolution ETF (ARKG) Overview

ARK Genomic Revolution ETF (ARKG) is an actively managed exchange-traded fund launched in 2014 that seeks long-term capital growth by investing primarily in equity securities of companies positioned to benefit from the genomics revolution. The fund typically holds 30–40 securities and maintains a non-diversified structure. Top holdings as of recent data include 10x Genomics Inc. (TXG), Twist Bioscience Corp. (TWST), Tempus AI Inc. (TEM), CRISPR Therapeutics AG (CRSP), and Personalis Inc. (PSNL), with individual weights frequently in the 5–10% range. Sector allocation centers overwhelmingly on healthcare, with secondary exposure to information technology. The expense ratio stands at 0.75%. ARKG’s active strategy relies on fundamental research to identify high-conviction opportunities in gene therapy, molecular diagnostics, and related innovations, resulting in a portfolio tilted toward smaller and mid-cap companies.

SPDR S&P Biotech ETF (XBI) Overview

SPDR S&P Biotech ETF (XBI) is a passively managed fund launched in 2006 that seeks to track the performance of the S&P Biotechnology Select Industry Index before fees and expenses. The index employs a modified equal-weight methodology across the biotechnology segment of the S&P Total Market Index. XBI typically holds approximately 150 securities, providing broad diversification within U.S. biotechnology. Top holdings generally represent 1–1.5% each, including names such as Apogee Therapeutics Inc. (APGE), Moderna Inc. (MRNA), Twist Bioscience Corp. (TWST), and Oruka Therapeutics Inc. (ORKA). The fund maintains nearly 100% exposure to healthcare, specifically biotechnology. Its expense ratio is 0.35%. The equal-weighted approach and sampling replication strategy result in a portfolio spanning market-capitalization tiers with lower single-stock concentration than many active peers.

Industry and Thematic Backdrop

The biotechnology sector continues to attract investor interest due to ongoing innovation in gene editing, cell therapies, and precision medicine. Macroeconomic factors including interest-rate expectations, regulatory pathways for drug approvals, and capital availability for clinical-stage companies influence sector dynamics. Capital flows into healthcare innovation remain sensitive to broader risk sentiment, while clinical trial outcomes and partnership announcements can drive individual company performance. Both ARKG and XBI operate within an environment characterized by high research-and-development intensity and potential for significant volatility tied to binary events such as regulatory decisions. Sector risks include clinical failure rates, reimbursement pressures, and competition from larger pharmaceutical firms.

Performance and Positioning Comparison

In recent market cycles, ARKG’s concentrated active bets have produced periods of outperformance during genomics-specific rallies but also sharper drawdowns when individual holdings faced setbacks. XBI’s diversified equal-weighted structure has delivered more consistent participation in broad biotechnology advances while mitigating the impact of any single stock’s underperformance. Relative positioning reflects differences in volatility profiles, with ARKG exhibiting greater sensitivity to thematic momentum in genomics and XBI providing steadier exposure across the wider biotech universe. Both funds respond to sector rotation driven by earnings cycles of key holdings, interest-rate movements affecting growth valuations, and macroeconomic shifts in healthcare spending and innovation funding.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Investors seeking data-driven insights on ETFs like ARKG or XBI may find the tool useful for refining research.

Tickeron AI Verdict

Based on observable structural factors, Tickeron’s AI would currently assign a higher probability of favor to SPDR S&P Biotech ETF (XBI). The lower expense ratio, greater number of holdings, modified equal-weighted methodology, and resulting diversification profile provide advantages in risk management and cost efficiency within the biotechnology sector. ARKG’s active thematic approach offers differentiated exposure but carries higher costs and concentration risk. Investors should evaluate both funds against individual objectives, time horizons, and risk tolerance.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations